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ABSTRACT
Introduction: Circulating prostaglandin E2 levels are
elevated in acutely decompensated cirrhosis and have
been shown to contribute to immune suppression.
Albumin binds and inactivates this hormone. Human
albumin solution could thus be repurposed as an
immune restorative drug in these patients.
This feasibility study aims to determine whether it is
possible and safe to restore serum albumin to >30 g/L
and maintain it at this level in patients admitted with
acute decompensated cirrhosis using repeated 20%
human albumin infusions according to daily serum
albumin levels.
Methods and analysis: Albumin To prevenT
Infection in chronic liveR failurE (ATTIRE) stage 1 is a
multicentre, open label dose feasibility trial. Patients
with acutely decompensated cirrhosis admitted to
hospital with a serum albumin of <30 g/L are eligible,
subject to exclusion criteria. Daily intravenous human
albumin solution will be infused, according to serum
albumin levels, for up to 14 days or discharge in all
patients. The primary end point is daily serum albumin
levels for the duration of the treatment period and the
secondary end point is plasma-induced macrophage
dysfunction. The trial will recruit 80 patients. Outcomes
will be used to assist with study design for an 866
patient randomised controlled trial at more than 30
sites across the UK.
Ethics and dissemination: Research ethics approval
was given by the London-Brent research ethics
committee (ref: 15/LO/0104). The clinical trials
authorisation was issued by the medicines and
healthcare products regulatory agency (ref: 20363/0350/
001-0001).
Results:Will be disseminated through peer reviewed
journals and international conferences. Recruitment of
the first participant occurred on 26/05/2015.
Trial registration number: The trial is registered with
the European Medicines Agency (EudraCT 2014-002300-
24) and has been adopted by the NIHR (ISRCTN
14174793). This manuscript refers to V.4.0 of the
protocol; Pre-results.
INTRODUCTION
Liver disease is the only major cause of mor-
tality currently increasing in the UK and is
the ﬁfth most common cause of death.1
These deaths are predicted to double over
the next 20 years.2
Patients with symptoms of liver failure sec-
ondary to cirrhosis are described as acute
decompensation (AD) patients. They are
highly prone to bacterial infection3 second-
ary to immune dysfunction,4 with nosocomial
(hospital-acquired) infection rates of 35%
compared to 5% in non-cirrhotic patients.5 6
Of those that develop infection with organ
dysfunction, 60–95% die, often following pro-
longed intensive care unit (ICU) admission.7
There is, however, no medical strategy to
restore immune competence.
It has been demonstrated that elevated cir-
culating prostaglandin E2 (PGE2) levels con-
tribute to immune suppression in AD
patients.8 The plasma protein albumin binds
and catalyses inactivation of PGE2.
9 Albumin
is synthesised in the liver and levels fall as the
synthetic function of the liver declines in
advanced cirrhosis, making PGE2 more bio-
available. In addition the binding capacity of
endogenous albumin is known to be defective
in cirrhosis.10 11 We found a serum albumin
of <30 g/L predicted plasma-induced macro-
phage dysfunction in a small cohort of AD
patients8 and this was reversed when albumin
levels were increased to >30 g/L.
Strengths and limitations of this study
▪ This study will demonstrate feasibility and safety
of targeted albumin dosing in patients with
acutely decompensated liver cirrhosis prior to a
large randomised controlled trial (RCT).
▪ Biomarker end point provides validation of a
novel biological assay for immune dysfunction.
▪ Outcomes will ensure optimal study protocol
design for the RCT.
▪ Feasibility study therefore not randomised or
powered to detect clinically relevant beneficial
outcomes.
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We propose a novel strategy to repurpose 20% human
albumin solution (HAS) as an immune restorative drug
in AD patients with the aim of maintaining serum
albumin at near normal levels.
Albumin To prevenT Infection in chronic liveR failurE
(ATTIRE) incorporates a phase II single-arm multicen-
tre feasibility trial (n=80) prior to a phase III rando-
mised controlled trial (RCT) (n=866) assessing the
impact of treatment on the incidence of nosocomial
infections, organ dysfunction and mortality in patients
admitted to hospital with AD of liver cirrhosis.
This feasibility trial aims to verify that daily intravenous
human albumin infusions will restore serum albumin
levels to near normal in AD patients, that this is safe and
that there is physician equipoise prior to proceeding to
a large RCT. Despite multiple studies, including system-
atic reviews,12 13 evaluating albumin in septic intensive
care patients there is a lack of interventional RCTs in
patients with liver cirrhosis in which the mechanism of
albumin’s action is different.14–16 To date there has not
been an albumin dosing trial aimed at increasing serum
albumin levels in this context therefore it was essential
that this was completed before proceeding to a large,
interventional RCT. We shall also examine the effects on
patient plasma-induced macrophage dysfunction using
assays developed within our laboratory8 which will valid-
ate the proposed mechanism of albumin’s action in
patients with chronic liver failure.
METHODS AND ANALYSIS
Primary objective
To determine whether it is possible to restore to and
maintain serum albumin at >30 g/L in patients admitted
with AD using repeated 20% HAS infusions according to
daily measured serum albumin levels (ﬁgure 1).
Secondary objective
We shall assess patient plasma-induced macrophage dys-
function (as an indicator of immune suppression) in AD
patients on the day of recruitment and during HAS
treatment to determine whether this is substantially
improved following albumin infusion.17
Trial design
This is a multicentre, open label single-arm feasibility
trial in which all patients will be treated with 20% HAS
to target levels above 30 g/L. Sequential patients admit-
ted to 10 UK participating hospitals with a clinical diag-
nosis of cirrhosis and AD will be screened using the
inclusion and exclusion criteria (table 1).
Clinical trial end points
The primary end point is daily serum albumin level for
the duration of the treatment period (maximum of
14 days or when the patient is considered ﬁt for dis-
charge if less than 14 days).
The key secondary end point is patient
plasma-induced macrophage dysfunction assessed by our
laboratory-based assays.8 Immune function is an
extremely complex process for which there is no simple
test or assay. During inﬂammation, monocytes move
quickly to sites of tissue infection and differentiate into
macrophages to elicit an immune response. Numerous
studies have demonstrated the role of monocyte deacti-
vation in cirrhosis associated immune suppression.18–20
It is, however, impractical to perform blinded, standar-
dised, biological assays using fresh monocytes from 10
sites spread throughout the UK. As it has been demon-
strated that circulating plasma mediators are responsible
for monocyte and neutrophil dysfunction,21 22 we devel-
oped an assay in which stored plasma from AD patients
is added to macrophages from healthy donors.8 This
permits testing of patient samples from multiple sites at
the same time in a controlled fashion.
We have selected macrophage production of the
proinﬂammatory cytokine tumour necrosis factor α
(TNF-α) as our immune-readout as this has been vali-
dated as a biomarker of monocyte function in critical
illness. Reduced capacity to produce TNF-α is associated
with adverse outcomes following sepsis.23 24
We will stimulate human monocyte-derived macro-
phages with lipopolysaccharide (LPS) in the presence of
25% patient plasma pretreatment and post-treatment,
measuring TNF-α production. LPS simulates a bacterial
infectious stimulus. Improvement in macrophage func-
tion will be deﬁned as an increase in LPS-induced
TNF-α production. Plasma from healthy controls will
also be used as a comparator.
Other secondary end points include rates of infection,
organ dysfunction and mortality during the 14-day treat-
ment period. Clinical data will also be collected regard-
ing safety, type of infection, antibiotic prescribing, total
amount of ﬂuid administered, ICU admission and dur-
ation of hospital stay.
Patient population
This will include all patients admitted to hospital with
complications of liver cirrhosis and serum albumin
<30 g/L, aged over 18 years with anticipated hospital
length of stay of ﬁve or more days at trial enrolment,
which should be no later than 72 h from admission.
This is subject to exclusion criteria as detailed in table 1.
The diagnosis of cirrhosis will be performed by the clin-
ical team as per standard UK practice and does not
require liver biopsy or imaging.
Consent
Patient information sheets (see online supplementary
appendix 1) will be given to and discussed with potential
patients before consent is sought. Informed consent will
be obtained from each participant or their legal repre-
sentative. Patients who lack mental capacity, for any
reason, are not excluded from the trial. An important
subgroup of patients will have hepatic encephalopathy
and these patients may lack capacity to consent.
However, these patients may be among those that
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receive maximum beneﬁt from the intervention.25–27 In
this case consent will be sought from an appropriate
legal representative independent of the research team as
per current UK clinical trials regulations.28
Intervention
All patients will receive a daily infusion of 20% HAS
intravenously (100mL/h) for a maximum of 14 days or
until discharge (if less than 14 days). The volume of
HAS prescribed each day will be determined by the
patient’s serum albumin level on that day.
Table 2 shows a suggested dosing protocol for albumin
administration. This is based on the reported regimen
used in the ALBIOS study29 and clinical experience as
there are no prior albumin dose–increment studies in
cirrhosis patients. In ALBIOS29 patients with a very low
albumin (<20 g/L) incremented to a higher value
within 4–5 days therefore we would expect 20% HAS
requirements, as according to our trial protocol, to
decrease after a few days with a subsequent decrease in
cost and time of administration. However, there may be
a subgroup of non-responders. We expect these patients
to be very unwell and careful monitoring of side effects
with on-going albumin infusion may warrant cessation of
the trial intervention in this group. If this is the case
additional time-to-increment advice may be added to
the RCT protocol.
Differing regimens may be used to cover large volume
paracentesis (8 g of albumin/L of ascites drained) or
treat hepatorenal syndrome (1 g of albumin/kg of body
weight) as per international guidelines30 31 but HAS
must be prescribed and given if serum albumin<35 g/L.
All variations will be recorded in the patient’s daily Case
Report Form (CRF).
Evaluations during and after treatment
Clinical, biochemical and microbiological data will be
collected daily during the trial treatment period (see
online supplementary appendix 2) using information
from hospital notes that is recorded as standard of care.
Figure 1 Protocol for ATTIRE
phase II feasibility trial. ATTIRE,
Albumin To prevenT Infection in
chronic liveR failurE.
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There is no follow-up beyond the treatment period. The
blood samples collected for immune function tests will
be analysed in a blinded fashion at a central site.
Statistical considerations
Sample size
The primary purpose of this Feasibility Trial is to demon-
strate that repeated 20% HAS infusions can raise and
maintain serum albumin at ≥30 g/L in liver cirrhosis
patients presenting with AD.
Eighty patients will be recruited. Success would be
demonstrated if 60% of patients were able to achieve
and maintain serum albumin levels at or above 30 g/L
on at least 1/3 of days in which the level is recorded. We
believe that there will be a subgroup of patients with
very low albumin levels who may not be able to achieve
this end point which has inﬂuenced our deﬁnition of
success. If our assumptions are correct these patients will
be excluded from RCT recruitment. With 72 evaluable
patients (allowing for 10% loss-to-follow-up/withdrawal)
the probability of achieving 44 or more ‘successes’ is
around 80% assuming that each patient has a 65%
chance of attaining the required level.
The trial will be performed at 10 sites. 8–10 patients
per site will allow identiﬁcation of any variability in the
delivery of the albumin-targeting dose protocol between
centres. It will be compulsory to record reason for proto-
col variation in the daily CRF.
Statistical evaluation
As this is a feasibility trial the emphasis will be on produ-
cing relevant data summaries rather than on formal
modelling or hypothesis testing. This will support the
IDMC and TSC in deciding whether to recommend pro-
ceeding with the RCT.
Primary outcome
Serum albumin levels will be summarised for each of
days 1–15 by table, mean±SD and graph (median level vs
day with superimposed bars displaying IQR). The
numbers of patients observed on each day will be noted.
Day 1 will represent the baseline serum albumin level
before the ﬁrst administration of 20% HAS according to
the protocol.
The number of patients on each day whose serum
albumin level exceeds 30 g/L will be noted as a percent-
age of those evaluated, together with the overall percent-
age of patients whose serum albumin level exceeds 30 g/L
on at least 1/3 of the days on which it is recorded.
Secondary outcomes
Albumin’s ex vivo impact on immune function will be
determined by comparing macrophage function in the
presence of patient plasma using our laboratory assays
when their albumin level is <30 g/L compared to
≥30 g/L. A substantial improvement in macrophage
function is expected following treatment with albumin.
Information shall be summarised regarding the total
volume of albumin infused and the total amount of
ﬂuid administered, days in ICU and duration of hospital
stay, together with the rates of nosocomial infections,
organ dysfunction and in-hospital mortality which are
the component elements of the composite end point for
the RCT. Safety will be assessed by consideration of the
number of SAEs reported during the trial.
Data will be further summarised within ‘groups’
deﬁned by baseline serum albumin levels (<20, 20–25
and 26–29 g/L) to investigate whether there are any
Table 1 Patient selection criteria
Patient inclusion criteria Patient exclusion criteria
All patients admitted to
hospital with acute onset or
worsening of complications
of cirrhosis
Advanced hepatocellular
carcinoma with life
expectancy of less than
8 weeks
Over 18 years of age Patients who will receive
palliative treatment only
during their hospital
admission
Predicted hospital
admission >5 days at trial
enrolment, which must be
within 72 h of admission
Patients who are pregnant
Serum albumin <30 g/L at
screening
Known or suspected severe
cardiac dysfunction
Documented informed
consent to participate (or
consent given by a legal
representative)
Any clinical condition which
the investigator considers
would make the patient
unsuitable for the trial
The patient has been
involved in a clinical trial of
Investigational Medicinal
Products (IMPs) within the
previous 30 days that would
impact on their participation
in this study
Trial investigators unable to
identify the patient (by NHS
number)
NHS, National Health Service.
Table 2 Dosing protocol for 20% HAS administration
(amounts per day) as advised by measured serum
albumin level on that day
Patient’s serum albumin
level (g/L)
Amount of 20%
HAS to be administered
(mL)
≥35 None
30–34 100
26–29 200
20–25 300
<20 400
HAS, human albumin solution.
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apparent differences in outcome by group. This sub-
group analysis is exploratory, since we are not powered
to detect differences, but may be useful in identifying
whether any amendments are necessary to the protocol
for the RCT.
DISCUSSION
ATTIRE is a UK multicentre trial that aims to evaluate
the repurposing of HAS as an immune restorative drug.
This protocol describes the feasibility trial which will
determine if it is possible and safe to raise and maintain
AD patients’ serum albumin levels to >30 g/L.
In liver cirrhosis current evidence-based guidance31–33
advocates the use of HAS in large volume paracentesis,34
hepatorenal syndrome35 and spontaneous bacterial peri-
tonitis.36 37 To date there has not been an albumin
dosing trial aimed at increasing serum albumin levels.
Therefore it was essential that this study was completed
before proceeding to a large, interventional RCT.
Studies evaluating the safety of HAS infusions have gen-
erally shown it to be a safe treatment.12 13 29 34 The main
concerns in the cirrhotic population are related to
volume overload leading to pulmonary oedema and
increase in portal pressure leading to variceal bleeding. A
recent interventional trial in septic AD patients reported
an 8.3% rate of pulmonary oedema in the albumin treat-
ment group.38 However, the weight based albumin dosing
regimen in this study led to much larger daily volumes of
albumin being prescribed than suggested in our proto-
col. This and other studies in cirrhosis have not reported
an increased incidence in variceal bleeding.34 37 39
We shall also correlate our primary end point of a
numerical increase in albumin levels with a biological
outcome measuring markers of immune function ex
vivo. This aims to verify that increasing serum albumin
above 30 g/L is associated with an improvement in
patient plasma-induced macrophage dysfunction ex vivo
in a much larger patient cohort than already shown.8
These outcomes will be used to move forward and if
appropriate modify the protocol for the ATTIRE RCT.
Ethics and dissemination
This research group will involve a potentially vulnerable
patient group that have hepatic encephalopathy and
therefore lack the capacity to consent. However, patients
with encephalopathy are at high risk of infection and
could be those that potentially receive maximal beneﬁt
from the intervention and therefore should not be
denied access to the trial treatment. We have undertaken
steps to ensure these patients are appropriately recruited
to the trial (described in ‘Consent’ section) and pro-
vided individual site training.
Research Ethics positive opinion was given by the
London-Brent Research Ethics Committee (ref: 15/LO/
0104) which specialise in trials involving patients who
lack the capacity to consent.
The Clinical Trials Authorisation was issued by the
Medicines and Healthcare products Regulatory Agency
(MHRA, ref: 20363/0350/001-0001). The trial is regis-
tered with the European Medicines Agency (EudraCT
2014-002300-24) and has been adopted by the NIHR.
Recruitment started in May 2015 and will ﬁnish by
November 2015. Assuming feasibility milestones have
been met a 866 patient phase III randomised control
trial (ATTIRE stage 2) will start at the end of 2015 ran-
domising patients to daily HAS infusion or routine
standard of care.
Study ﬁndings will be disseminated through peer
reviewed publications and international conference pre-
sentations. They will also be used to generate the study
protocol for a large interventional RCT (ATTIRE stage 2).
Trial funding and sponsor
The work is supported by the Health Innovation
Challenge fund (Wellcome Trust and Department of
Health) award number 164699. The trial sponsor is
UCL with trial management activities conducted by the
UCL Comprehensive Clinical Trials Unit.
TRIAL MANAGEMENT AND MONITORING
Research Steering Group
The Research Steering Group (RSG) operates on behalf
of the funders to ensure that appropriate milestones
have been met in the delivery of the trial. It consists the
CI, an independent expert and representatives of the
Welcome Trust and Department of Health.
Trial Management Group
The Trial Management Group (TMG) comprises the CI,
Clinical Research Fellow, Clinical Project Manager, Trial
Statistician, Trial Manager, Data Manager, Health
Economist and ﬁve trial site PIs. The TMG is responsible
for developing the design, co-ordination and strategic
management of the trial.
Trial Steering Committee
The Trial Steering Committee (TSC) is the independent
group responsible for oversight of the trial in order to
safeguard the interests of trial patients. The TSC pro-
vides advice to the CI, Clinical Trials Unit (CTU),
funder and sponsor on all aspects of the trial through its
independent chair.
Independent Data Monitoring Committee
The Independent Data Monitoring Committee (IDMC)
is responsible for safeguarding the interests of trial
patients, monitoring the accumulating data and making
recommendations to the TSC on whether the trial
should continue as planned. It comprises a clinical chair
(independent hepatologist), independent gastroenter-
ologist and an independent statistician all with expertise
in Clinical Trials.
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